Bailard’s ProPhase Labs PRPH Stock Holding History

Bailard’s Portfolio PRPH Stock Details PRPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,120	Closed	-$126K	–	770
2022 Q3	$126K	Buy	+1,120	New	+$130K	0.01%	624

Other funds holding PRPH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AWE

Avidian Wealth Enterprises Houston, Texas $3.16B AUM 20.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Navellier & Associates Reno, Nevada $960M AUM 79.37% 1-Year Est. Return

Bailard's PRPH Position: Q4 2022 in Review

Bailard sold out of ProPhase Labs (PRPH) in Q4 2022, closing a stake of 1,120 shares — an estimated $126K sold.

Bailard first reported a position in PRPH in Q3 2022 and held it in 1 quarter. The position peaked at $126K in Q3 2022. 51 funds tracked by Wall St. Rank hold PRPH as of Q4 2022.

Bailard reported no remaining ProPhase Labs position as of Q4 2022 after selling out during the quarter.
Bailard sold 1,120 ProPhase Labs shares in Q4 2022, an estimated $126K.
Bailard first reported a position in ProPhase Labs in Q3 2022 and held it in 1 quarter.
Bailard's ProPhase Labs position peaked at $126K in Q3 2022.
51 funds tracked by Wall St. Rank held ProPhase Labs as of Q4 2022.

Based on Bailard's 13F filing for Q4 2022, filed 2 Feb 2023.